REPL Q2'26 Earnings: EPS estimate is (0.78) USD

What happened

Replimune Group is set to announce its Q2'26 results on October 29 at 8:00 AM ET, with a revenue estimate of 0 USD and an anticipated loss per share of 0.78.

Confirmed

Global impact / market context

An expected loss per share of 0.78 with no expected revenue means investors will judge Replimune mainly on drug pipeline progress and how quickly it spends cash, since there are no sales to offset costs.

Analyst inference

Prior quarters show Replimune repeatedly missing both revenue and earnings estimates, so expectations are already low. That history means a smaller-than-expected loss or any drug development update could matter more than the headline numbers.

Analyst inference

What to watch

1. Watch whether the reported loss per share comes in better or worse than the 0.78 estimate when Replimune announces Q2'26 results on October 29. Confirmed
2. Watch for comment on how fast Replimune is using its cash, since without revenue, the company's ability to fund research depends on its existing cash balance. Analyst inference
3. Watch for any update on regulatory filings or trial progress for Replimune's drug candidates, as these milestones are likely to shape how investors value the company. Proposed

Evidence

• Original source link unavailable